KAPA BAYRY kairos Pharma announces strategic collaboration with Bayer to enhance xofigo activity in metastatic prostate cancer Kairos Pharma
KAPA BAYRY kairos Pharma announces strategic collaboration with Bayer to enhance xofigo activity in metastatic prostate cancer Kairos Pharma: to evaluate Co's lead antibody env-105 with Bayer's xofigo in metastatic castration-resistant prostate cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.